<DOC>
	<DOCNO>NCT01647984</DOCNO>
	<brief_summary>Study role combination nutraceuticals ( Ritmonutra ) effect benign supraventricular ventricular extrasystole subject free specific organic heart disease . It suggest treatment nutritional supplement , able normalize 'cardiac electrophysiology ' help maintain wellness . Ritmonutra ® combination nutraceuticals® , include Omega-3 polyunsaturated fatty acid , Hawthorn , Astaxanthin Vitamin E , help normalize heart pacing , reduce total number benign extrasystoles consequently improve quality life .</brief_summary>
	<brief_title>Role Combination Nutraceuticals ( Ritmonutra ) Benign Supraventricular Ventricular Arrhythmias</brief_title>
	<detailed_description>Benign supraventricular ventricular extrasystole may frequently occur subject free specific organic heart disease . use potent anti-arrhythmic indicated kind arrhythmias occurrence type extrasystole may generate concern patient consequently bad quality life . 1 . Study Rationale Supraventricular ventricular extrasystole may frequently occur subject free specific organic heart disease . The prognosis arrhythmia benign clinical indication perform periodic medical examination confirm absence organic heart disease follow . Treatment benign arrhythmias n't require use potent anti-arrhythmic drug potential side effect . However , occurrence type extrasystole may generate concern patient despite assurance physician , consequently bad quality life . For reason suggest treatment nutritional supplement , able normalize 'cardiac electrophysiology ' help maintain wellness . Ritmonutra ® combination nutraceuticals demonstrate efficacy preserve physiological cardiovascular function addition adequate diet . Ritmonutra ® classify Ministry Health food supplement Notification 26 Settmbre 2011 . The functional component Ritmonutra ® , include Omega-3 polyunsaturated fatty acid , Hawthorn , Astaxanthin Vitamin E , help normalize pace , reduce total number benign extrasystole , consequently improve quality life . According preliminary study perform patient benign extrasystole , supraventricular ventricular , free specific heart disease , Ritmonutra ® demonstrate significant effect reduce number total extrasystole improve wellness subject . In particular , Ritmonutra ® show improve social life individual reduce limitation cause emotional state , without side effect . 2 . AIM OF THE STUDY Aim study investigate whether addition Ritmonutra addition adequate diet improve normalize regular rhythm patient free specific organic cardiovascular disease compare mere placebo . Moreover , patient symptomatic benign extrasytoles , investigator want evaluate whether nutraceutical supplement reduce discomfort relate perceive arrhythmia consequently improve life quality . 3 . STUDY DESIGN multicentre , randomize , control parallel-group study . 4 . STUDY POPULATION The study include participation one clinic centre coordinate 150 general practitioner ( GPs ) . Each GP select least 10 subject gender , All participant give write informed consent protocol approve local institutional review board . At least 150 doctor take part study ; treat least 10 subject gender diagnosis symptomatic benign ventricular supraventricular extrasytoles , free specific organic cardiovascular disease require pharmacological therapy . Indicators : GPs require : 1 ) record full medical history , include smoke drinking habit , base pre-defined clinical record ; 2 ) collect demographic anthropometric measure ( height , weight , waist circumference iliac crest ) ; 3 ) perform complete physical exam . At first visit 4 8 week eligible patient perform complete physical exam include measure office blood pressure heart rate sit position triplicate , use manual sphygmomanometer , accord international guideline . Measurements round close 2 mmHg interval . The baseline visit others screen visit also include Electrocardiogram ( ECG ) , Ergometric test , Echocardiogram Holter ECG . The primary endpoint reduction total number extrasystole . Secondary endpoint : improvement wellness subject consequently life quality . 4.1 . Sample size The estimate sample size perform SISA method ( Simple Interactive Statistical Analysis ) - Machin , David Campbell , Michael J . ( 1987 ) Statistical Tables Design Clinical Trials . Blackwell Scientific Publications , Boston . Based value previous preliminary study compare Ritmonutra ® control group ( -58.5 % reduction total extrasystoles 4 week Ritmonutra ® compare with-0.5 % control group ) approximate estimate make number observation necessary two percentage significant 5 % probability level : 12 subject case group . 5 . TREATMENTS All subject receive dietary counseling determine general practitioner depend subject 's clinical condition , accordance instruction Coordinating Site . Centralized randomization use assign subject one two study treatment , Inert Placebo - Vitamin B complex + diet vitamin B complex - Ritmonutra ® + diet . How Ritmonutra take : 2 tavgel gum daily Ritmonutra ® vitamin B complex 2 tablet chew day . Duration treatment : Subjects group take assign treatment 4 week . Ritmonutra ® contains : 720 mg Fish Oil Omega-3 , include 480 mg EPA 40 mg DHA , Hawthorn ( extract Crataegus mongyna ) 300 mg equivalent 5.4 mg vitexin , 4 mg Astaxanthin 36 mg Vitamin E. 6 . EVALUATION CRITERIA At baseline , 4 8 week cardiovascular parameter ( blood pressure , heart rate , Holter ECG ) SF-36 quality life questionnaire 4SQ_2011questionnaire investigate somatic symptom related stress assess well others clinical parameter necessary evaluate cardiovascular risk change life quality . 7 . STUDY PROCEDURES Each doctor initially give login password allow confidential individual access website www.ritmonutra.net data entry . In order avoid sample error , doctor include study first 10 consecutive subject meet admission criterion ( see point 4 ) . The doctor complete appropriate form ( also available ritmonutra.net site ) insert information point 0 assign subject one two regimen , Inert Placebo - Vitamin B complex + diet vitamin B complex - Ritmonutra ® + diet , base determine centralized randomization responsibility Prof. Bruno Trimarco delivery subject treatment require 4 week ( Ritmonutra ® control ) . After four week subject go Holter ECG , SF-36 4SQ_2011 . After first four week patient receive alternative treatment provide randomization ( control - Ritmonutra ® ) . After another four week subject underwent 24-Hour Holter ( ECG ) monitoring , SF-36 4SQ_2011 . 8 . STATISTICAL ANALYSIS The statistical analysis baseline homogeneity undertaken use chi-square test analysis variance , appropriate . The statistical analysis ass clinical efficacy base comparison difference various time point versus baseline obtain two treatment group conduct use chi-square test analysis variance , appropriate . The level significance consider Alfa = 0.05 ( type I error ) power level beta = 0.90 ( type II error ) . 9 . STUDY TIMELINES The study start time login password deliver . 10 . AVAILABILITY OF DATA All participant inform result data process . 11 . COORDINATING COMMITTEE For clarification study contact : Dr. Claudio Benvenuti - Medical Management Rottapharm | Madaus Valosa via di Sopra , 9-20900 Monza tel 039 7390406 - Fax 039 7390393 email : @ claudio.benvenuti rottapharm.com .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Diagnosis ventricular atrial extrasystole Presence organic cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Arrhythmias</keyword>
	<keyword>Life quality</keyword>
</DOC>